Role of P2Y1 purinoceptor in ADP-induced platelet activation

ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induce...

Full description

Saved in:
Bibliographic Details
Published inFEBS letters Vol. 422; no. 3; pp. 291 - 295
Main Authors Savi, P, Beauverger, P, Labouret, C, Delfaud, M, Salel, V, Kaghad, M, Herbert, J.M
Format Journal Article
LanguageEnglish
Published England Elsevier B.V 06.02.1998
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [ 33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [ 33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone.
AbstractList ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [ 33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [ 33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone.
ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone.
ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone.ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone.
ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP‐induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [ 33 P]2‐MeS‐ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [ 33 P]2‐MeS‐ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti‐ADP agent. A3P5PS specifically inhibited 2‐MeS‐ADP‐induced shape change and calcium increase but did not affect adenylyl cyclase down‐regulation. 2‐MeS‐ADP‐induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non‐aggregating compound, therefore suggesting that P2Y1‐mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP‐induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone.
Author Savi, P
Beauverger, P
Kaghad, M
Labouret, C
Delfaud, M
Salel, V
Herbert, J.M
Author_xml – sequence: 1
  givenname: P
  surname: Savi
  fullname: Savi, P
– sequence: 2
  givenname: P
  surname: Beauverger
  fullname: Beauverger, P
– sequence: 3
  givenname: C
  surname: Labouret
  fullname: Labouret, C
– sequence: 4
  givenname: M
  surname: Delfaud
  fullname: Delfaud, M
– sequence: 5
  givenname: V
  surname: Salel
  fullname: Salel, V
– sequence: 6
  givenname: M
  surname: Kaghad
  fullname: Kaghad, M
– sequence: 7
  givenname: J.M
  surname: Herbert
  fullname: Herbert, J.M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/9498802$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1L5TAUhsPgoFednyB0JbqokzRtc4KC-O2AoMy4cRXa5BQivU1NUsV_b9t7ceHGWQXyfuScJ9tko3MdErLH6BGjrPz9j1KWp4WQ_EDCIaU0K1L4QRYMBE95XsIGWXxatsh2CM-jiQGTm2RT5hKAZgty8te1mLgmecieWNIP3nZOYx-dT2yXnF0-pLYzg0aT9G0VscWYVDra1ypa1-2Sn03VBvy1PnfI4_XV48Vtend_8-fi7C7VBQdIdQnMcJCF0VlmgJqywIpzwVGwmkohjQZoJOdFKUqd5TWr66IuDWvGPTnwHbK_qu29exkwRLW0QWPbVh26ISghRcZkLkbj3to41Es0qvd2Wfl3td521IuVrr0LwWPz6WBUTVDVDFVNxJQENUNV0wDHX3LaxplA9JVtv03frtJvtsX3_3tSXV-dZ7MyCRLm66nqdFWFI-1Xi14FbbEbv8d61FEZZ78Z5gMJBqIA
CitedBy_id crossref_primary_10_1002_wmts_97
crossref_primary_10_1038_sj_bjp_0704673
crossref_primary_10_1080_09537100410001682788
crossref_primary_10_1124_mol_64_5_1210
crossref_primary_10_1046_j_1538_7836_2003_00003_x
crossref_primary_10_1074_jbc_274_41_29108
crossref_primary_10_1080_09537100701708498
crossref_primary_10_1007_s40256_019_00345_5
crossref_primary_10_1172_JCI8399
crossref_primary_10_1182_blood_V97_3_587
crossref_primary_10_1080_09537100600757794
crossref_primary_10_1074_jbc_274_40_28293
crossref_primary_10_1016_S0165_1838_00_00136_3
crossref_primary_10_1016_j_atherosclerosis_2008_08_023
crossref_primary_10_1074_jbc_M110714200
crossref_primary_10_1016_S0014_5793_98_01049_7
crossref_primary_10_1182_blood_2005_07_3040
crossref_primary_10_1182_blood_V99_1_193
crossref_primary_10_1038_ki_2008_613
crossref_primary_10_1016_j_jep_2021_114306
crossref_primary_10_1515_BC_2000_051
crossref_primary_10_1007_s00424_011_1010_x
crossref_primary_10_1124_mol_117_109660
crossref_primary_10_1046_j_1365_2141_1998_01056_x
crossref_primary_10_1074_jbc_M207256200
crossref_primary_10_1172_JCI12242
crossref_primary_10_1517_14656566_6_5_755
crossref_primary_10_1021_jm4013906
crossref_primary_10_1007_s12185_012_1188_5
crossref_primary_10_1038_sj_bjp_0703046
crossref_primary_10_1073_pnas_0510446103
crossref_primary_10_2165_00003495_200060020_00012
crossref_primary_10_1007_s11302_011_9247_6
crossref_primary_10_1177_1536012120927609
crossref_primary_10_3390_brainsci3020540
crossref_primary_10_1016_S0014_2999_98_00985_6
crossref_primary_10_2492_inflammregen_26_446
crossref_primary_10_1006_phrs_2001_0861
crossref_primary_10_1161_01_RES_0000251742_71301_16
crossref_primary_10_1016_j_jmgm_2006_09_006
crossref_primary_10_1097_00001721_200404000_00001
crossref_primary_10_1182_blood_2002_02_0642
crossref_primary_10_1016_S0006_2952_00_00279_3
crossref_primary_10_1038_sj_bjp_0704486
crossref_primary_10_1074_jbc_M407783200
crossref_primary_10_1080_0953710031000092794
crossref_primary_10_1111_j_1365_2141_2010_08499_x
crossref_primary_10_1038_13522
crossref_primary_10_1007_s11302_012_9303_x
crossref_primary_10_1161_01_ATV_0000057809_32354_22
crossref_primary_10_1016_S0014_5793_99_01313_7
crossref_primary_10_1006_bbrc_1999_9558
crossref_primary_10_1073_pnas_95_14_8070
crossref_primary_10_1182_blood_V99_9_3228
crossref_primary_10_1039_C1AY05530E
crossref_primary_10_1002__SICI_1098_2299_199810_45_2_67__AID_DDR3_3_0_CO_2_C
crossref_primary_10_1111_j_1538_7836_2004_00556_x
crossref_primary_10_1097_00062752_200109000_00002
crossref_primary_10_1182_blood_2005_02_0725
crossref_primary_10_1038_sj_bjp_0702690
crossref_primary_10_1182_blood_V94_12_4156_424k29_4156_4165
crossref_primary_10_1002_rth2_12149
crossref_primary_10_1002__SICI_1098_2299_199811_12_45_3_4_135__AID_DDR8_3_0_CO_2_B
crossref_primary_10_1046_j_1365_2141_2003_04166_x
crossref_primary_10_1093_eurheartj_sul047
crossref_primary_10_1016_S0026_895X_24_12601_6
crossref_primary_10_1182_blood_V94_12_4156
crossref_primary_10_1002_ddr_1117
crossref_primary_10_1007_s11302_015_9462_7
crossref_primary_10_1152_ajpheart_00110_2002
crossref_primary_10_1007_BF02982079
crossref_primary_10_1146_annurev_pharmtox_46_120604_141207
crossref_primary_10_1002_cmdc_201402141
crossref_primary_10_1016_j_ijbiomac_2016_12_002
crossref_primary_10_1152_physrev_00003_2005
crossref_primary_10_1161_01_ATV_19_10_2281
crossref_primary_10_1016_j_bcmd_2005_12_024
crossref_primary_10_1002_ddr_1108
crossref_primary_10_1007_s40265_013_0126_z
crossref_primary_10_1046_j_1538_7836_2003_00266_x
crossref_primary_10_1592_phco_26_3_388
crossref_primary_10_1002_ddr_1109
crossref_primary_10_1038_sj_bjp_0703816
crossref_primary_10_1097_00019501_200302000_00008
crossref_primary_10_1182_blood_V96_6_2134
crossref_primary_10_1016_S0014_2999_99_00201_0
crossref_primary_10_1097_00005344_200204000_00008
crossref_primary_10_1016_S0165_6147_98_01271_1
crossref_primary_10_1016_j_pharmthera_2009_10_008
crossref_primary_10_1016_j_pharmthera_2005_03_009
crossref_primary_10_1515_LabMed_2002_064
crossref_primary_10_1007_s12265_012_9445_9
crossref_primary_10_1016_S0165_1838_00_00151_X
crossref_primary_10_1124_pr_58_3_3
crossref_primary_10_1161_01_CIR_103_5_718
crossref_primary_10_1046_j_0014_2956_2001_02448_x
crossref_primary_10_3390_molecules23020374
crossref_primary_10_1006_bbrc_2001_4816
crossref_primary_10_1016_S0898_6568_00_00083_8
crossref_primary_10_1172_JCI12818
crossref_primary_10_1211_jpp_61_04_0014
crossref_primary_10_1182_blood_V96_10_3439_h8003439_3439_3446
crossref_primary_10_1016_S0014_2999_98_00305_7
crossref_primary_10_1161_01_ATV_19_8_2007
crossref_primary_10_1111_j_1538_7836_2006_02192_x
crossref_primary_10_1016_S0049_3848_99_00124_3
crossref_primary_10_1093_abbs_gmr023
crossref_primary_10_1038_84667
crossref_primary_10_1038_sj_bjp_0703517
crossref_primary_10_1182_blood_V96_6_2134_h8002134_2134_2139
crossref_primary_10_1007_s11302_011_9227_x
crossref_primary_10_1055_s_0040_1714745
crossref_primary_10_1111_j_1538_7836_2007_02866_x
crossref_primary_10_1161_01_CIR_100_15_1667
crossref_primary_10_1182_blood_V96_10_3439
Cites_doi 10.1006/bbrc.1996.0139
10.1046/j.1365-2141.1997.3133126.x
10.1016/S0014-5793(97)00022-7
10.1042/bj2630377
10.1016/0049-3848(82)90061-5
10.1042/bj3120775
10.1016/S0021-9258(19)36687-6
10.1113/jphysiol.1985.sp015850
10.1042/bj2840923
10.1016/S0140-6736(96)09457-3
10.1016/0378-1119(96)00027-3
10.1016/S0021-9258(19)83641-4
10.1136/jcp.19.2.148
10.1016/0014-5793(82)81234-9
10.1182/blood.V52.2.453.453
10.1046/j.1365-2141.1997.d01-2132.x
10.1042/bj1760083
10.1055/s-0038-1650012
10.1006/bbrc.1996.0640
10.1016/0049-3848(94)90186-4
10.1016/0009-8981(80)90378-2
10.1016/S0165-6147(96)01038-3
10.1002/(SICI)1098-1128(199603)16:2<159::AID-MED2>3.0.CO;2-#
10.1111/j.1527-3466.1993.tb00275.x
10.1055/s-0038-1650674
10.1038/194927b0
ContentType Journal Article
Copyright 1998 Federation of European Biochemical Societies
FEBS Letters 422 (1998) 1873-3468 © 2015 Federation of European Biochemical Societies
Copyright_xml – notice: 1998 Federation of European Biochemical Societies
– notice: FEBS Letters 422 (1998) 1873-3468 © 2015 Federation of European Biochemical Societies
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/S0014-5793(98)00025-8
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Biology
EISSN 1873-3468
EndPage 295
ExternalDocumentID 9498802
10_1016_S0014_5793_98_00025_8
FEB2S0014579398000258
S0014579398000258
Genre article
Journal Article
GroupedDBID ---
--K
-~X
.55
.~1
0R~
0SF
1B1
1OC
1~.
1~5
24P
29H
2WC
33P
4.4
4G.
53G
5GY
5RE
5VS
6I.
7-5
71M
8P~
AABNK
AACTN
AAEDW
AAESR
AAFTH
AAHHS
AAIKJ
AAJUZ
AALRI
AANLZ
AAQFI
AAQXK
AASGY
AAXRX
AAXUO
AAZKR
ABBQC
ABCUV
ABEFU
ABFNM
ABFRF
ABGSF
ABHUG
ABJNI
ABLJU
ABMAC
ABQWH
ABVKL
ABXDB
ABXGK
ACAHQ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIUM
ACMXC
ACNCT
ACPOU
ACXBN
ACXQS
ADAWD
ADBBV
ADBTR
ADDAD
ADEOM
ADEZE
ADIYS
ADKYN
ADMGS
ADMUD
ADOZA
ADQTV
ADUVX
ADXAS
ADZMN
ADZOD
AEEZP
AEFWE
AEGXH
AEKER
AENEX
AEQDE
AEQOU
AEUQT
AEUYR
AEXQZ
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFVGU
AFZJQ
AGHFR
AGJLS
AGYEJ
AHBTC
AHPSJ
AI.
AIACR
AIAGR
AITUG
AIURR
AIWBW
AJBDE
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AMYDB
AZFZN
AZVAB
BAWUL
BFHJK
BMXJE
C45
CBWCG
CS3
DCZOG
DIK
DOVZS
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FUBAC
G-Q
GBLVA
GI5
GX1
HVGLF
HZ~
IHE
IXB
J1W
KBYEO
L7B
LATKE
LCYCR
LEEKS
LITHE
LOXES
LUTES
LX3
LYRES
M41
MEWTI
MO0
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MVM
MXFUL
MXMAN
MXSTM
N9A
NCXOZ
O-L
O9-
OK1
OVD
OZT
P-8
P-9
P2P
P2W
PC.
Q38
R2-
R9-
RIG
RNS
ROL
RPZ
SCC
SDF
SDG
SDP
SEL
SES
SEW
SFE
SSZ
SUPJJ
SV3
TEORI
TR2
UHB
UNMZH
VH1
WBKPD
WH7
WIH
WIJ
WIK
WIN
WOHZO
WXSBR
X7M
XFK
Y6R
YK3
ZA5
ZGI
ZZTAW
~02
AAHBH
AAHQN
AAIPD
AAMNL
AAYCA
ABWVN
ACRPL
ADNMO
ADVLN
AFWVQ
AITYG
AKRWK
ALUQN
ALVPJ
HGLYW
AAYWO
AAYXX
ACVFH
ADCNI
AEUPX
AEYWJ
AFPUW
AGQPQ
AGYGG
AIGII
AKBMS
AKYEP
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PKN
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ID FETCH-LOGICAL-c5388-c681d3895dc22d80d65ea3373e71b0979dc88f9335676c24b1bb5b6d1f016383
IEDL.DBID .~1
ISSN 0014-5793
IngestDate Fri Jul 11 03:14:22 EDT 2025
Wed Feb 19 02:33:24 EST 2025
Tue Jul 01 03:51:42 EDT 2025
Thu Apr 24 23:01:21 EDT 2025
Wed Jan 22 16:33:00 EST 2025
Fri Feb 23 02:32:43 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Adenosine diphosphate
Platelet aggregation
P2Y1 purinoceptor
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
http://onlinelibrary.wiley.com/termsAndConditions#vor
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5388-c681d3895dc22d80d65ea3373e71b0979dc88f9335676c24b1bb5b6d1f016383
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0014579398000258
PMID 9498802
PQID 79721947
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_79721947
pubmed_primary_9498802
crossref_primary_10_1016_S0014_5793_98_00025_8
crossref_citationtrail_10_1016_S0014_5793_98_00025_8
wiley_primary_10_1016_S0014_5793_98_00025_8_FEB2S0014579398000258
elsevier_sciencedirect_doi_10_1016_S0014_5793_98_00025_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate February 06, 1998
PublicationDateYYYYMMDD 1998-02-06
PublicationDate_xml – month: 02
  year: 1998
  text: February 06, 1998
  day: 06
PublicationDecade 1990
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle FEBS letters
PublicationTitleAlternate FEBS Lett
PublicationYear 1998
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Rink, Smith, Tsien (BIB28) 1982; 148
Savi, Bornia, Salel, Delfaud, Herbert (BIB29) 1997; 98
Léon, Vial, Cazenave, Gachet (BIB16) 1996; 171
Janssens, Communi, Pirotton, Samson, Parmentier, Boeynaems (BIB15) 1996; 221
Peerschke, Zucker (BIB27) 1980; 43
Siess, Lapetina (BIB26) 1989; 263
Born (BIB10) 1962; 194
CAPRIE Steering Committee (1996) Lancet 348, 1329–1339.
Meurs, Kauffman, Koeter, Devries (BIB12) 1980; 106
Mills (BIB5) 1996; 76
Savi, Laplace, Maffrand, Herbert (BIB14) 1994; 269
Bachelot, Cano, Grelac, Saleun, Druker, Levy-Toledano, Fischer, Rendu (BIB22) 1992; 284
Hallam, Scrutton, Wallis (BIB25) 1982; 27
Sambrook, J., Fritsh, E.F. and Maniatis, T. (1989) in: Molecular Cloning. A Laboratory Manual, 2nd edn., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Léon, Hechler, Vial, Leray, Cazenave, Gachet (BIB6) 1997; 403
Ohlmann, Laugwitz, Nurnberg, Spicher, Schultz, Cazenave, Gachet (BIB30) 1995; 312
Colman, R.W. (1987) in: Modern Methods in Pharmacology (Colman, R.W., Ed.), Vol. 4. Methods for Studying Platelets and Megakaryocytes, pp. 33–40, Alan R. Liss, New York.
Bouaboula, Legoux, Pessegue, Delpech, Dumont, Piechacyk, Casellas, Shire (BIB9) 1992; 267
Mustard, Packham, Kinlough-Rathbone, Perry, Regoeczi (BIB24) 1978; 52
O'Brien, Heywood (BIB19) 1966; 19
Hallam, Rink (BIB20) 1985; 368
Fredholm, Abbracchio, Burnstock, Dubyak, Harden, Jacobson, Schwabe, Williams (BIB4) 1997; 18
Ayyanathan, Webbs, Sandhu, Athwal, Barnar, Kunapuli (BIB17) 1996; 218
Haslam, Davidson, Desjardins (BIB21) 1978; 176
Savi, Herbert (BIB3) 1996; 16
Savi, Laplace, Herbert (BIB7) 1994; 76
Grynkiewicz, Poenie, Tsien (BIB13) 1985; 260
Herbert, Frehel, Vallée, Kieffer, Gouy, Berger, Necciari, Defreyn, Maffrand (BIB1) 1993; 11
Boyer, Romero-Avila, Schachter, Harden (BIB18) 1996; 50
Savi, Artcanuthurry, Bornia, Grelac, Maclouf, Levy-Toledano, Herbert (BIB23) 1997; 97
1966; 19
1992; 284
1978; 52
1992; 267
1980; 43
1996; 50
1985; 368
1978; 176
1996; 221
1982; 148
1995; 312
1996; 16
1985; 260
1996; 76
1980; 106
1997; 403
1982; 27
1994; 269
1997; 98
1997; 97
1993; 11
1989; 263
1962; 194
1997; 18
1996; 171
1996; 218
1994; 76
Boyer J.L. (e_1_2_4_19_1) 1996; 50
Savi P. (e_1_2_4_15_1) 1994; 269
e_1_2_4_21_1
e_1_2_4_20_1
e_1_2_4_23_1
e_1_2_4_22_1
e_1_2_4_25_1
e_1_2_4_24_1
e_1_2_4_27_1
e_1_2_4_26_1
e_1_2_4_29_1
e_1_2_4_28_1
e_1_2_4_3_1
e_1_2_4_2_1
e_1_2_4_5_1
e_1_2_4_4_1
e_1_2_4_7_1
e_1_2_4_6_1
e_1_2_4_9_1
e_1_2_4_8_1
e_1_2_4_30_1
e_1_2_4_10_1
e_1_2_4_31_1
e_1_2_4_11_1
e_1_2_4_12_1
e_1_2_4_13_1
e_1_2_4_14_1
e_1_2_4_16_1
e_1_2_4_18_1
e_1_2_4_17_1
References_xml – reference: Sambrook, J., Fritsh, E.F. and Maniatis, T. (1989) in: Molecular Cloning. A Laboratory Manual, 2nd edn., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
– volume: 97
  start-page: 185
  year: 1997
  end-page: 191
  ident: BIB23
  publication-title: Br. J. Haematol.
– volume: 11
  start-page: 180
  year: 1993
  end-page: 198
  ident: BIB1
  publication-title: Cardiovasc. Drug Rev.
– reference: CAPRIE Steering Committee (1996) Lancet 348, 1329–1339.
– reference: Colman, R.W. (1987) in: Modern Methods in Pharmacology (Colman, R.W., Ed.), Vol. 4. Methods for Studying Platelets and Megakaryocytes, pp. 33–40, Alan R. Liss, New York.
– volume: 50
  start-page: 1323
  year: 1996
  end-page: 1329
  ident: BIB18
  publication-title: Mol. Pharmacol.
– volume: 19
  start-page: 148
  year: 1966
  end-page: 153
  ident: BIB19
  publication-title: J. Clin. Pathol.
– volume: 27
  start-page: 435
  year: 1982
  end-page: 445
  ident: BIB25
  publication-title: Thromb. Res.
– volume: 267
  start-page: 21830
  year: 1992
  end-page: 21838
  ident: BIB9
  publication-title: J. Biol. Chem.
– volume: 284
  start-page: 923
  year: 1992
  end-page: 928
  ident: BIB22
  publication-title: Biochem. J.
– volume: 260
  start-page: 3440
  year: 1985
  end-page: 3450
  ident: BIB13
  publication-title: J. Biol. Chem.
– volume: 194
  start-page: 927
  year: 1962
  end-page: 929
  ident: BIB10
  publication-title: Nature
– volume: 312
  start-page: 775
  year: 1995
  end-page: 779
  ident: BIB30
  publication-title: Biochem. J.
– volume: 171
  start-page: 295
  year: 1996
  end-page: 297
  ident: BIB16
  publication-title: Gene
– volume: 98
  start-page: 880
  year: 1997
  end-page: 886
  ident: BIB29
  publication-title: Br. J. Haematol.
– volume: 263
  start-page: 377
  year: 1989
  end-page: 385
  ident: BIB26
  publication-title: Biochem. J.
– volume: 76
  start-page: 835
  year: 1996
  end-page: 856
  ident: BIB5
  publication-title: Thromb. Haemost.
– volume: 269
  start-page: 772
  year: 1994
  end-page: 777
  ident: BIB14
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 52
  start-page: 453
  year: 1978
  end-page: 466
  ident: BIB24
  publication-title: Blood
– volume: 16
  start-page: 159
  year: 1996
  end-page: 179
  ident: BIB3
  publication-title: Med. Res. Rev.
– volume: 106
  start-page: 91
  year: 1980
  end-page: 97
  ident: BIB12
  publication-title: Clin. Chim. Acta
– volume: 148
  start-page: 21
  year: 1982
  end-page: 26
  ident: BIB28
  publication-title: FEBS Lett.
– volume: 403
  start-page: 26
  year: 1997
  end-page: 30
  ident: BIB6
  publication-title: FEBS Lett.
– volume: 18
  start-page: 79
  year: 1997
  end-page: 82
  ident: BIB4
  publication-title: Trends Pharmacol. Sci.
– volume: 218
  start-page: 783
  year: 1996
  end-page: 788
  ident: BIB17
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 43
  start-page: 58
  year: 1980
  end-page: 60
  ident: BIB27
  publication-title: Thromb. Haemost.
– volume: 176
  start-page: 83
  year: 1978
  end-page: 95
  ident: BIB21
  publication-title: Biochem. J.
– volume: 76
  start-page: 157
  year: 1994
  end-page: 169
  ident: BIB7
  publication-title: Thromb. Res.
– volume: 368
  start-page: 131
  year: 1985
  end-page: 146
  ident: BIB20
  publication-title: J. Physiol.
– volume: 221
  start-page: 588
  year: 1996
  end-page: 593
  ident: BIB15
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 148
  start-page: 21
  year: 1982
  end-page: 26
  publication-title: FEBS Lett.
– volume: 218
  start-page: 783
  year: 1996
  end-page: 788
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 19
  start-page: 148
  year: 1966
  end-page: 153
  publication-title: J. Clin. Pathol.
– volume: 260
  start-page: 3440
  year: 1985
  end-page: 3450
  publication-title: J. Biol. Chem.
– volume: 97
  start-page: 185
  year: 1997
  end-page: 191
  publication-title: Br. J. Haematol.
– volume: 269
  start-page: 772
  year: 1994
  end-page: 777
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 312
  start-page: 775
  year: 1995
  end-page: 779
  publication-title: Biochem. J.
– volume: 76
  start-page: 157
  year: 1994
  end-page: 169
  publication-title: Thromb. Res.
– volume: 267
  start-page: 21830
  year: 1992
  end-page: 21838
  publication-title: J. Biol. Chem.
– volume: 106
  start-page: 91
  year: 1980
  end-page: 97
  publication-title: Clin. Chim. Acta
– volume: 52
  start-page: 453
  year: 1978
  end-page: 466
  publication-title: Blood
– volume: 76
  start-page: 835
  year: 1996
  end-page: 856
  publication-title: Thromb. Haemost.
– volume: 284
  start-page: 923
  year: 1992
  end-page: 928
  publication-title: Biochem. J.
– volume: 263
  start-page: 377
  year: 1989
  end-page: 385
  publication-title: Biochem. J.
– volume: 11
  start-page: 180
  year: 1993
  end-page: 198
  publication-title: Cardiovasc. Drug Rev.
– volume: 176
  start-page: 83
  year: 1978
  end-page: 95
  publication-title: Biochem. J.
– volume: 368
  start-page: 131
  year: 1985
  end-page: 146
  publication-title: J. Physiol.
– volume: 43
  start-page: 58
  year: 1980
  end-page: 60
  publication-title: Thromb. Haemost.
– volume: 403
  start-page: 26
  year: 1997
  end-page: 30
  publication-title: FEBS Lett.
– volume: 194
  start-page: 927
  year: 1962
  end-page: 929
  publication-title: Nature
– volume: 16
  start-page: 159
  year: 1996
  end-page: 179
  publication-title: Med. Res. Rev.
– volume: 221
  start-page: 588
  year: 1996
  end-page: 593
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 50
  start-page: 1323
  year: 1996
  end-page: 1329
  publication-title: Mol. Pharmacol.
– volume: 98
  start-page: 880
  year: 1997
  end-page: 886
  publication-title: Br. J. Haematol.
– volume: 171
  start-page: 295
  year: 1996
  end-page: 297
  publication-title: Gene
– volume: 27
  start-page: 435
  year: 1982
  end-page: 445
  publication-title: Thromb. Res.
– volume: 18
  start-page: 79
  year: 1997
  end-page: 82
  publication-title: Trends Pharmacol. Sci.
– ident: e_1_2_4_12_1
– ident: e_1_2_4_18_1
  doi: 10.1006/bbrc.1996.0139
– ident: e_1_2_4_30_1
  doi: 10.1046/j.1365-2141.1997.3133126.x
– ident: e_1_2_4_7_1
  doi: 10.1016/S0014-5793(97)00022-7
– ident: e_1_2_4_27_1
  doi: 10.1042/bj2630377
– ident: e_1_2_4_26_1
  doi: 10.1016/0049-3848(82)90061-5
– ident: e_1_2_4_31_1
  doi: 10.1042/bj3120775
– ident: e_1_2_4_10_1
  doi: 10.1016/S0021-9258(19)36687-6
– ident: e_1_2_4_21_1
  doi: 10.1113/jphysiol.1985.sp015850
– ident: e_1_2_4_23_1
  doi: 10.1042/bj2840923
– ident: e_1_2_4_3_1
  doi: 10.1016/S0140-6736(96)09457-3
– ident: e_1_2_4_17_1
  doi: 10.1016/0378-1119(96)00027-3
– ident: e_1_2_4_14_1
  doi: 10.1016/S0021-9258(19)83641-4
– ident: e_1_2_4_20_1
  doi: 10.1136/jcp.19.2.148
– ident: e_1_2_4_29_1
  doi: 10.1016/0014-5793(82)81234-9
– ident: e_1_2_4_25_1
  doi: 10.1182/blood.V52.2.453.453
– volume: 50
  start-page: 1323
  year: 1996
  ident: e_1_2_4_19_1
  publication-title: Mol. Pharmacol.
– ident: e_1_2_4_24_1
  doi: 10.1046/j.1365-2141.1997.d01-2132.x
– ident: e_1_2_4_22_1
  doi: 10.1042/bj1760083
– ident: e_1_2_4_28_1
  doi: 10.1055/s-0038-1650012
– ident: e_1_2_4_16_1
  doi: 10.1006/bbrc.1996.0640
– ident: e_1_2_4_8_1
  doi: 10.1016/0049-3848(94)90186-4
– ident: e_1_2_4_9_1
– ident: e_1_2_4_13_1
  doi: 10.1016/0009-8981(80)90378-2
– ident: e_1_2_4_5_1
  doi: 10.1016/S0165-6147(96)01038-3
– ident: e_1_2_4_4_1
  doi: 10.1002/(SICI)1098-1128(199603)16:2<159::AID-MED2>3.0.CO;2-#
– ident: e_1_2_4_2_1
  doi: 10.1111/j.1527-3466.1993.tb00275.x
– ident: e_1_2_4_6_1
  doi: 10.1055/s-0038-1650674
– volume: 269
  start-page: 772
  year: 1994
  ident: e_1_2_4_15_1
  publication-title: J. Pharmacol. Exp. Ther.
– ident: e_1_2_4_11_1
  doi: 10.1038/194927b0
SSID ssj0001819
Score 1.9896551
Snippet ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA...
SourceID proquest
pubmed
crossref
wiley
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 291
SubjectTerms Adenosine diphosphate
Adenosine Diphosphate - physiology
Animals
Calcium - metabolism
Clopidogrel
Humans
In Vitro Techniques
P2Y1 purinoceptor
Platelet Activation - drug effects
Platelet Activation - physiology
Platelet aggregation
Platelet Aggregation Inhibitors - pharmacology
Polymerase Chain Reaction
Rabbits
Receptors, Purinergic P2 - drug effects
Receptors, Purinergic P2 - physiology
Receptors, Purinergic P2Y1
Ticlopidine - analogs & derivatives
Ticlopidine - pharmacology
Title Role of P2Y1 purinoceptor in ADP-induced platelet activation
URI https://dx.doi.org/10.1016/S0014-5793(98)00025-8
https://onlinelibrary.wiley.com/doi/abs/10.1016%2FS0014-5793%2898%2900025-8
https://www.ncbi.nlm.nih.gov/pubmed/9498802
https://www.proquest.com/docview/79721947
Volume 422
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-lRfRFamvxtNY8iOhD2s3HbhLoy97Zo1qQUiqeT-HysXBw7h61ffDFv91JstujFKn4tht2wjAzO_PLZCZB6C11Vlgf818QDIlwXhDtOSVl4_zcA17QudriS3X6VXyelbMNNBl6YWJZZe_7s09P3rofOeqlebRaLGKPLxUlmJdW8bcuY8OvEDJa-eHvdZkHRLAMgakg8et1F0-eIQ2-1-pDmoSov8Wn-_jzLpxN8Wi6jZ72QBLXmddnaCO0O2i3bmER_eMXfodTaWfKme-gR-Ph6fFkuOBtFx1fdMuAuwafs-8Ur2LavYtFLt0VXrS4_nhOYL0Omvd4tQRECgrGsQsi53Cfo8vpyeXklPSXKRAHPk0RVwEyBYWU3jHmVeGrMsw5lzxIagsttXdKNZrzspKVY8JSa0tbedoUEbLxPbTZdm14gbAElMeq4Atvg2BAVjWwzOBOScd5cHSExCBB4_qDxuN9F0uzrigDwZsoeKOVSYI3aoQOb8lW-aSNhwjUoB5zx2QMRIOHSN8M6jQg9LhHMm9Dd_PTyHiakRZyhPaylm950UKDr2MjVCet_xuPZnoyZvcs9eX_c_4KPcldkYwU1T7avL66Ca8BFl3bg2T3B2irPrv4dgZvn2bjPzqi_nw
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB9qReqL1NbS86PNg4g-pN1NstkEfLlee5xaS5ET6lO4fCwcnLtHbR988W93kt3tUYq0-LaEnTDMJDO_TGYyAG9zZ4X1Mf6FzpAK5wXVnue0qJyfecQLus22OJOT7-LzRXGxBqO-FiamVXa2v7XpyVp3I4edNA-X83ms8c1FgctLq7itC_UIHgvcvrGNwcGfVZ4HurAWA-eCxt9XZTztFGnwvVYf0ixU_ctB3QWgt_FsckjjTXjWIUkybJl9Dmuh3oLtYY2n6J-_yTuScjtT0HwLnhz1XxujvsPbNnz81iwCaSpyzn7kZBnj7k3Mcmkuybwmw-Nzigd2VL0nywVCUtQwiWUQbRD3BUzHJ9PRhHbdFKhDqSjqJEJT1EjhHWNeZV4WYcZ5yUOZ20yX2julKs15IUvpmLC5tYWVPq-yiNn4DqzXTR12gZQI85gMPvM2CIZkssJzBneqdJwHlw9A9BI0rntpPDa8WJhVShkK3kTBG61MErxRAzi4IVu2T23cR6B69Zhba8agO7iPdL9Xp0Ghx0uSWR2a61-mjM8ZaVEOYKfV8g0vWmg0dmwAw6T1h_FoxidH7M5Sffn_nO_DxmT69dScfjr78gqetiWSjGbyNaxfXV6HN4iRruxe2gN_AQ0o_vE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+P2Y1+purinoceptor+in+ADP-induced+platelet+activation&rft.jtitle=FEBS+letters&rft.au=Savi%2C+P&rft.au=Beauverger%2C+P&rft.au=Labouret%2C+C&rft.au=Delfaud%2C+M&rft.date=1998-02-06&rft.pub=Elsevier+B.V&rft.issn=0014-5793&rft.eissn=1873-3468&rft.volume=422&rft.issue=3&rft.spage=291&rft.epage=295&rft_id=info:doi/10.1016%2FS0014-5793%2898%2900025-8&rft.externalDocID=S0014579398000258
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-5793&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-5793&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-5793&client=summon